This topic contains a solution. Click here to go to the answer

Author Question: In a pretest-posttest nonequivalent control group design, having a control group can help rule out ... (Read 111 times)

geodog55

  • Hero Member
  • *****
  • Posts: 530
In a pretest-posttest nonequivalent control group design, having a control group can help rule out the confounding effects of
 
  a. history, maturation, and regression to the mean.
  b. age, experimenter bias, and Hawthorne-type effects.
  c. gender bias, selection, and interviewer bias.
  d. interpretation bias, falsification of data, and instrumentation.

Question 2

In scientific methodology, researchers tend to pursue four different goals: 1) description; 2) prediction; 3) understanding; and 4)
 
  a. proving
  b. funding
  c. publication
  d. application



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

chereeb

  • Sr. Member
  • ****
  • Posts: 326
Answer to Question 1

a

Answer to Question 2

d




geodog55

  • Member
  • Posts: 530
Reply 2 on: Jun 20, 2018
Great answer, keep it coming :)


epscape

  • Member
  • Posts: 335
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

In women, pharmacodynamic differences include increased sensitivity to (and increased effectiveness of) beta-blockers, opioids, selective serotonin reuptake inhibitors, and typical antipsychotics.

Did you know?

Colchicine is a highly poisonous alkaloid originally extracted from a type of saffron plant that is used mainly to treat gout.

Did you know?

The human body's pharmacokinetics are quite varied. Our hair holds onto drugs longer than our urine, blood, or saliva. For example, alcohol can be detected in the hair for up to 90 days after it was consumed. The same is true for marijuana, cocaine, ecstasy, heroin, methamphetamine, and nicotine.

Did you know?

Autoimmune diseases occur when the immune system destroys its own healthy tissues. When this occurs, white blood cells cannot distinguish between pathogens and normal cells.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library